# Neurona Therapeutics

> Clinical-stage biotherapeutics company in South San Francisco, California, developing allogeneic
> regenerative neural cell therapies for chronic disorders of the nervous system. Lead candidate
> NRTX-1001 (rezanecel) is an inhibitory interneuron cell therapy for drug-resistant mesial temporal
> lobe epilepsy. Acquired by UCB S.A.; the acquisition completed 2026-06-02.

This llms.txt was generated by API Evangelist from the public company profile in
`apis.yml`. Neurona Therapeutics does not publish an llms.txt of its own
(https://www.neuronatherapeutics.com/llms.txt returned HTTP 404 on 2026-08-26).

## API surface

Neurona Therapeutics publishes **no public API**. Contract discovery on 2026-08-26 probed the only
host the company operates (www.neuronatherapeutics.com) for `/openapi.json`, `/openapi.yaml`,
`/swagger.json`, `/v1/openapi.json`, `/api-docs`, `/docs`, `/redoc`, `/graphql`, `/api`,
`/developers`, `/wp-json/`, and the full `/.well-known/` discovery set including
`/.well-known/agent-card.json` and `/.well-known/agent.json`. Every path returned HTTP 404, and a
negative-control path returned the same 404, so these are genuine absences rather than a soft-404
catch-all. No GitHub organization, npm, or PyPI package attributable to the company was found.

## Company

- [Website](https://www.neuronatherapeutics.com/): Corporate home
- [About](https://www.neuronatherapeutics.com/about/): Founding at UCSF, leadership, and mission
- [Technology](https://www.neuronatherapeutics.com/technology/): Regenerative inhibitory neuron cell therapy platform
- [Pipeline](https://www.neuronatherapeutics.com/pipeline/): NRTX-1001 and clinical programs (NTE001, NTE002, Phase 3 EPIC)
- [Press Releases](https://www.neuronatherapeutics.com/news/press-releases/): Company news
- [Careers](https://www.neuronatherapeutics.com/careers/): Open roles
- [Contact](https://www.neuronatherapeutics.com/contact/): 490 Forbes Blvd, Suite 600, South San Francisco, CA 94080

## Legal

- [Terms of Use](https://www.neuronatherapeutics.com/terms-of-use/)
- [Privacy Policy](https://www.neuronatherapeutics.com/privacy-policy/)

## Corporate ownership

- [UCB S.A.](https://www.ucb.com): Parent company
- [Acquisition announcement](https://www.ucb.com/newsroom/press-releases/article/ucb-completes-acquisition-of-neurona-therapeutics-advancing-its-leadership-as-innovator-in-epilepsy-through-regenerative-science): UCB completed the acquisition of Neurona Therapeutics on 2026-06-02

## Artifacts in this profile

- [Domain security](security/neurona-therapeutics-domain-security.yml): Probed TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture
- [Well-known probe](well-known/neurona-therapeutics-well-known.yml): Measured absence of every /.well-known/ document
- [Plans](plans/neurona-therapeutics-plans-pricing.yml): plan_count 0 — no software product, no pricing page
- [Rate limits](rate-limits/neurona-therapeutics-rate-limits.yml): limit_count 0 — no API to limit